

19 - References

References

20 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

1. Royal College of Psychiatrists. The Risks and Benefits of High-Dose Antipsychotic Medication. College Report CR190. London: Royal College of Psychiatrists; 2014.
2. Paton C, et al. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. *Br J Psychiatry* 2008; 192:435–439.
3. Roh D, et al. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. *Aust N Z J Psychiatry* 2014; 48:52–60.
4. Campos Mendes J, et al. Patterns of antipsychotics' prescription in Portuguese acute psychiatric wards: a cross-sectional study. *Psychiatry Res* 2016; 246:142–148.
5. Martinho S, et al. Antipsychotic polypharmacy and high-dose antipsychotics in involuntary patients: a seven-year audit of discharge prescriptions in an acute care unit. *Psychiatr Q* 2021; 92:1–14.
6. Kaikoushi K, et al. Prescription patterns in psychiatric compulsory care: polypharmacy and high-dose antipsychotics. *BJPsych Open* 2021; 7:e149.
7. Patel MX, et al. Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales. *Eur Neuropsychopharmacol* 2014; 24:499–509.
8. Royal College of Psychiatrists. Prescribing Observatory for Mental Health. Topic 1h & 3e: Prescribing of antipsychotic medication in adult mental health services, including high dose, combined, and PRN. CCQI 422. 2022 (last accessed February 2025); <https://www.rcpsych.ac.uk/improving-care/ccqi/national-clinical-audits/pomh>.
9. Davis JM, et al. Dose response and dose equivalence of antipsychotics. *J Clin Psychopharmacol* 2004; 24:192–208.
10. Gardner DM, et al. International consensus study of antipsychotic dosing. *Am J Psychiatry* 2010; 167:686–693.
11. Ezewuzie N, et al. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. *J Psychopharm* 2006; 20:86–90.
12. Sparshatt A, et al. Quetiapine: dose-response relationship in schizophrenia. *CNS Drugs* 2008; 22:49–68.
13. Kinon BJ, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. *J Clin Psychopharmacol* 2008; 28:392–400.
14. Bishara D, et al. Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. *J Clin Psychopharmacol* 2013; 33:329–335.

15. Meltzer HY, et al. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia. *Schizophr Res* 2014; 154:14-22.
16. Goff DC, et al. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. *J Clin Psychopharmacol* 2013; 33:485-490.
17. Egerton A, et al. Dopamine and glutamate in antipsychotic-responsive compared with antipsychotic-nonresponsive psychosis: a multicenter positron emission tomography and magnetic resonance spectroscopy study (STRATA). *Schizophr Bull* 2021; 47:505-516.
18. Kapur S, et al. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. *Am J Psychiatry* 2000; 157:514-520.
19. Demjaha A, et al. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. *Am J Psychiatry* 2012; 169:1203-1210.
20. Gillespie AL, et al. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. *BMC Psychiatry* 2017; 17:12.
21. Dold M, et al. Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials. *Schizophr Res* 2015; 166:187-193.
22. Agid O, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. *J Clin Psychiatry* 2011; 72:1439-1444.
23. Aubree JC, et al. High and very high dosage antipsychotics: a critical review. *J Clin Psychiatry* 1980; 41:341-350.
24. Boggs DL, et al. Quetiapine at high doses for the treatment of refractory schizophrenia. *Schizophr Res* 2008; 101:347-348.
25. Meltzer HY, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. *J Clin Psychiatry* 2008; 69:274-285.
26. Souza JS, et al. Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. *CNS Spectr* 2013; 18:82-89.
27. Gannon L, et al. High-dose olanzapine in treatment-resistant schizophrenia: a systematic review. *Ther Adv Psychopharmacol* 2023; 13:20451253231168788.
28. Leucht S, et al. Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. *Am J Psychiatry* 2020; 177:342-353.
29. Loebel A, et al. Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study. *J Clin Psychiatry* 2016; 77:1672-1680.
30. McAdam MK, et al. Second International Consensus Study of Antipsychotic Dosing (ICSAD--2). *J Psychopharmacol* 2023; 37:982-991.
31. Sifakis S, et al. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. *Mol Psychiatry* 2023; 28:3267-3277.
32. Yoshida K, et al. Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia. *Behav Brain Res* 2021; 402:113098.

33. Wu H, et al. Antipsychotic-induced weight gain: dose-response meta-analysis of randomized controlled trials. *Schizophr Bull* 2022; 48:643-654.
34. He L, et al. A real-world study of risk factors for QTc prolongation in schizophrenia patients receiving atypical antipsychotics. *J Clin Psychopharmacol* 2022; 42:71-74.
35. Osborn DP, et al. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. *Arch Gen Psychiatry* 2007; 64:242-249.

Schizophrenia and related psychoses CHAPTER 1

36. Ray WA, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. *N Engl J Med* 2009; 360:225-235.
37. Barbui C, et al. Antipsychotic dose mediates the association between polypharmacy and corrected QT interval. *PLoS One* 2016; 11:e0148212.
38. Weinmann S, et al. Influence of antipsychotics on mortality in schizophrenia: systematic review. *Schizophr Res* 2009; 113:1-11.
39. Honer WG, et al. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. *J Clin Psychiatry* 2012; 73:13-20.
40. Bollini P, et al. Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. *Psychol Med* 1994; 24:307-316.
41. Baldessarini RJ, et al. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. *Arch Gen Psychiatry* 1988; 45:79-90.
42. Kawai N, et al. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. *Prog Neuropsychopharmacol Biol Psychiatry* 2006; 30:1009-1014.

Revision #1

Created 2026-01-04 20:13:05 UTC by Omar Ayman

Updated 2026-01-04 20:13:05 UTC by Omar Ayman